Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.62T
24h Vol:
$3.20B
Dominance:
MSFT:5.15%
Stocklytics Platform
BETA
Instrument logo  PFE

Pfizer Inc

PFE
62 / 100
S&P500
$26.97arrow_drop_down-0.77%-$0.21

Performance History

Stocklytics logo
Key Stats
Open$27.63
Prev. Close$27.76
EPS0.37
Dividend$1.64
Next Earnings DateMay 28, 2024
Dividend Yield %6.05%
Market Cap$153.64B
PE Ratio73.59
LOWHIGH
Day Range27.07
27.64
52 Week Range25.76
42.22
Ratios
P/B Ratio1.62
Revenue$100.33B
Operating M. %-49.97%
Earnings$2.11B
Earnings Growth %-93.25%
EBITDA Margin %11.48%
ROE %2.35%
EPS0.37

Score Breakdown

62vs 53. Market Avg.

All Score 62 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

PFEMARKET
Value5439
Quality5340
Ownership3119
Growth4846
Dividends5837
check_circle

Pfizer Inc's Price discount from 1 year high of 33.57% is great compared to market average of 16.4%. This indicates PFE could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$769.99
24H (%)arrow_drop_up0.05%
24H ($)$0.45
MARKET CAP$731.03B
PRICE$525.88
24H (%)arrow_drop_down-0.25%
24H ($)-$1.35
MARKET CAP$486.50B
PRICE$160.82
24H (%)arrow_drop_down-0.63%
24H ($)-$1.02
MARKET CAP$387.49B
PRICE$128.88
24H (%)arrow_drop_down-0.44%
24H ($)-$0.57
MARKET CAP$326.66B

About Pfizer Inc (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Drug Manufacturers—General
CEO
Dr. Albert Bourla D.V.M., DVM, Ph.D.
Headquarters
New York
Employees
83000
Exchange
NYSE
add Pfizer Inc to watchlist

Keep an eye on Pfizer Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Pfizer Inc's (PFE) price per share?

The current price per share for Pfizer Inc (PFE) is $27.23. The stock has seen a price change of -$0.53 recently, indicating a -1.91% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Pfizer Inc (PFE)?

For Pfizer Inc (PFE), the 52-week high is $42.22, which is 55.05% from the current price. The 52-week low is $25.76, the current price is 5.71% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Pfizer Inc (PFE) a growth stock?

Pfizer Inc (PFE) has shown an average price growth of -1.63% over the past three years. It has received a score of 50 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Pfizer Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Pfizer Inc (PFE) stock price performance year to date (YTD)?

As of the latest data, Pfizer Inc (PFE) has a year-to-date price change of -8.5%. Over the past month, the stock has experienced a price change of -0.86%. Over the last three months, the change has been -9.65%. Looking at a longer horizon, the five-year price change stands at -33.23%.

question_mark
Is Pfizer Inc (PFE) a profitable company?

Pfizer Inc (PFE) has a net income of $2.12B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 65.77% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -49.97% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $100.33B, with a revenue growth rate of 23.43%, providing insight into the company's sales performance and growth. The gross profit is $65.99B. Operating income is noted at $40.03B. Furthermore, the EBITDA is $45.1B.

question_mark
What is the market capitalization of Pfizer Inc (PFE)?

Pfizer Inc (PFE) has a market capitalization of $153.65B. The average daily trading volume is 32.86M, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.